About us

The AndzonBio^® model proposes a suite of Pipeline Builder Companies to accelerate the development of the most promising academic projects in life sciences.

AndzonBio^® Pipeline Builder Companies are built on the conviction that focusing on specific therapeutic areas, combined with a hands-on, expert-driven approach, is the key to unlock the full potential of each academic project.

AndzonBio^® Pipeline Builder Companies are built on the conviction that focusing on specific therapeutic areas, combined with a hands-on, expert-driven approach, is the key to unlock the full potential of each academic project.

With a dedicated leadership team of seasoned biotech professionals and a rich network of industry leaders, AndzonBio1 is ideally positioned to capture and develop well-differentiated and high-potential CVRM assets with:
• Rigorous process to select the most promising projects
• Leverage on an established network of world-leading experts and top tier CROs
• Comprehensive development plan
• Clear path to value generation and company growth

All academic projects identified and evaluated must have exceptional potential to contribute to building a pipeline of programs bringing breakthrough innovations developed by strong and recognized KOLs, new targets of interest and first-in-class therapy potential. Overall, eachcompany’s pipeline program shall contribute to addressing urgent unmet medical needs and be capable of meeting the interest of strategic partners.

Discover AndzonBio Model

Why focusing on CVRM?

100s of Millions
of people globally live
with CVRM disease

98% of patients
with type 2
diabetes have at least
one other CVRM disease

40-50% of patients
with heart failure have
chronic kidney disorders

CardioVascular, Renal & Metabolic diseases still represent a major unmet medical need and are the main leading cause of death globally due to several factors such as:
• High prevalence and co-morbidities: multiple prevalent diseases often coexist and exacerbate each other. For example, people with type 2 diabetes have a significantly higher risk of developing cardiovascular disease and chronic kidney disease. This interconnection creates a complex health burden
• Lifestyle factors: Unhealthy diets, lack of physical activity are prevalent risk factors that contribute to this spectrum of diseases. These lifestyle factors are difficult to manage on a global scale.
• Aging: As the global population ages, the incidence of these diseases increases. Older adults are more susceptible to CVRM disorders, leading to higher mortality rates.
• Insufficient medical progress: Despite clear advances in medical research, there are still gaps in effective treatments and preventive measures. The complexity of these diseases requires new and more integrated therapeutic approaches.

Addressing these challenges requires multifaceted approaches, including public health initiatives, lifestyle interventions, and continued biomedical research to develop more effective treatments and preventive strategies.

DIABETES
AFFECTS
410 MILLION
PEOPLE
WITH AN OVER

70%
INCREASE

IN FATALITIES
SINCE 2000

RESULTING IN
1.5 MILLION
DEATHS
PER YEAR

KIDNEY
DISEASE
AFFECTS
APPROXIMATELY
700 MILLION
PEOPLE
WITH A

40% INCREASE
IN PATIENTS NEEDING
DIALYSIS

IN FATALITIES
SINCE 2000

SINCE 1990
AND CAUSES
1.5 MILLION
DEATHS
PER YEAR

STROKES
CAUSE OVER

6.5 MILLION
DEATHS
PER YEAR
AND AFFECT
101 MILLION
PEOPLE

WITH CASES
ON THE RISE

HEART
DISEASE
IS BECOMING

MORE
PREVALENT

AFFECTING AROUND
26 MILLION
PEOPLE

AND CAUSING
9 MILLION
DEATHS
PER YEAR

LIVER
DISEASE

AFFECT
AN ESTIMATED
1.5 BILLION
PEOPLE
AND AS MANY AS

40% OF THE
ADULT POPULATION

IN SOME COUNTRIES
LEADING TO
2 MILLION
DEATHS
PER YEAR

From owlstone medical 2022

Team

AndzonBio1 is relying on a leadership team composed of highly skilled biotech professionals with complementary expertise, and an outstanding Scientific Advisory Board composed of top-tier experts, bringing a strong blend of experience in Drug Development and CVRM expertise.